These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31060635)

  • 1. Dopamine antagonist antipsychotics in diverted forensic populations.
    Cummings MA; Proctor GJ; Arias AW
    CNS Spectr; 2020 Apr; 25(2):128-135. PubMed ID: 31060635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can typical and atypical antipsychotics show differential effectiveness in treating paranoia and hallucinations in schizophrenia?
    Osimo EF; Goujon MJ; Perez J; Murray GK
    BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30936353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
    Ebdrup BH; Raghava JM; Nielsen MØ; Rostrup E; Glenthøj B
    J Psychiatry Neurosci; 2016 Mar; 41(2):133-41. PubMed ID: 26599135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring and improving antipsychotic adherence in outpatient forensic diversion programs.
    Meyer JM
    CNS Spectr; 2020 Apr; 25(2):136-144. PubMed ID: 31120002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.
    Gross G; Wicke K; Drescher KU
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):155-66. PubMed ID: 23128852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.
    Fervaha G; Caravaggio F; Mamo DC; Mulsant BH; Pollock BG; Nakajima S; Gerretsen P; Rajji TK; Mar W; Iwata Y; Plitman E; Chung JK; Remington G; Graff-Guerrero A
    Psychopharmacology (Berl); 2016 Oct; 233(21-22):3803-3813. PubMed ID: 27557949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
    Kramer MS; Last B; Getson A; Reines SA
    Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.
    Moriguchi S; Bies RR; Remington G; Suzuki T; Mamo DC; Watanabe K; Mimura M; Pollock BG; Uchida H
    J Clin Psychopharmacol; 2013 Oct; 33(5):682-5. PubMed ID: 23899638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin-dopamine antagonists and treatment of negative symptoms.
    Carpenter WT
    J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):30S-35S. PubMed ID: 7730498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients.
    Suzuki A; Mihara K; Kondo T; Tanaka O; Nagashima U; Otani K; Kaneko S
    Pharmacogenetics; 2000 Jun; 10(4):335-41. PubMed ID: 10862524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology of schizophrenia and the role of newer antipsychotics.
    Risch SC
    Pharmacotherapy; 1996; 16(1 Pt 2):11-4. PubMed ID: 8778681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
    Kapur S; Remington G
    Annu Rev Med; 2001; 52():503-17. PubMed ID: 11160792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report.
    Suzuki A; Kondo T; Mihara K; Yasui-Furukori N; Otani K; Furukori H; Kaneko S; Inoue Y
    Eur Arch Psychiatry Clin Neurosci; 2001; 251(2):57-9. PubMed ID: 11407439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between risperidone plasma levels and dopamine D2 occupancy: a positron emission tomographic study.
    Remington G; Kapur S; Zipursky R
    J Clin Psychopharmacol; 1998 Feb; 18(1):82-3. PubMed ID: 9472848
    [No Abstract]   [Full Text] [Related]  

  • 19. Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention.
    Gomes FV; Grace AA
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
    Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.